Section 12 AAC 52.240 - Pharmacist collaborative practice authority(a) A pharmacist planning to exercise collaborative practice authority in the pharmacist's practice by initiating or modifying drug therapy, in accordance with a written protocol established and approved for the pharmacist's practice by a practitioner authorized to prescribe drugs under AS 08, must submit the completed written protocol to the board,(b) A written protocol must include (1) an agreement in which practitioners authorized to prescribe legend drugs in this state authorize pharmacists licensed in this state to administer or dispense in accordance with that written protocol;(2) a statement identifying the practitioners authorized to prescribe and the pharmacists who are party to the agreement;(3) the time period during which the written protocol will be in effect, not to exceed two years;(4) the types of collaborative authority decisions that the pharmacists are authorized to make, including (A) types of diseases, drugs, or drug categories involved and the type of collaborative authority authorized in each case; and(B) procedures, decision criteria, or plans the pharmacists are to follow when making therapeutic decisions, particularly when modification or initiation of drug therapy is involved;(5) activities the pharmacists are to follow in the course of exercising collaborative authority, including documentation of decisions made, and a plan for communication and feedback to the authorizing practitioners concerning specific decisions made;(6) a list of the specific types of patients eligible to receive services under the written protocol;(7) a plan for the authorizing practitioners to review the decisions made by the pharmacists at least once every three months; and(8) a plan for providing the authorizing practitioners with each patient record created under the written protocol; and(10) an acknowledgement that the authorizing practitioner will not receive any compensation from a pharmacist or pharmacy as a result of the care or treatment of any patient under the agreement.(c) To enter into a written protocol under this section, practitioners authorized to prescribe must be in active practice, and the authority granted must be within the scope of the practitioners' practice.(e) Documentation related to the written protocol must be maintained for at least two years.(f) An authorizing practitioner or a pharmacist may terminate the written protocol upon written notice. The pharmacist shall notify the board in writing not more than 30 days after a written protocol is terminated.(g) Any modification to the written protocol must be submitted to the board as required by this section for a new written protocol.(h) This section does not apply to participation, by a pharmacist practicing in an institutional facility in drug therapy protocols and guidelines approved by the institutional facility's pharmacy and therapeutics committee or by another medical staff governing body of that institutional facility, if records related to the drug therapy protocols and guidelines are maintained and made available to the board upon request.(i) A signed copy of the protocols must remain at the pharmacy location at all times.Eff. 11/10/2001, Register 160; am 2/11/2004, Register 169; am 11/16/2012, Register 204; am 10/31/2019, Register 232, January 2020; am 1/19/2024, Register 249, April 2024; am 9/28/2024, Register 251, October 2024Authority:AS 08.80.030
AS 08.80.480